HLA Antibodies: Formation, Transfusion Risks, Transplant Rejection, and Management

What Are HLA Antibodies?

HLA (Human Leukocyte Antigen) antibodies are immunoglobulins directed against foreign HLA proteins (class I: HLA-A, -B, -C; class II: HLA-DR, -DQ, -DP). They develop after exposure to non-self HLA.

Sensitizing Events

• Blood transfusion (especially pre-leukoreduction era)
• Organ transplantation
• Pregnancy (fetal HLA from father)
• Previous transplant rejection

Clinical Consequences

• Transfusion Reactions: Febrile non-hemolytic (FNHTR), platelet refractoriness, TRALI (anti-HLA class II).
• Transplant Rejection: Antibody-mediated rejection (AMR) — donor-specific antibodies (DSA) bind graft endothelium → complement activation, microvascular injury, graft loss.

Management Strategies

• Transfusion: HLA-matched platelets for refractory patients; washed/irradiated products.
• Transplant: Virtual crossmatch (DSA screening), desensitization (plasmapheresis, IVIG, rituximab, bortezomib), paired exchange, acceptable mismatch programs.
• Monitoring: Serial DSA testing post-transplant (Luminex single antigen beads).

HLA antibody profiling is essential for safe transfusion and transplant outcomes.